WEE1 Inhibitor: Clinical Development
Anthony Kong1,2, Hisham Mehanna3
1Institute of Head and Neck Studies (InHANSE), University of Birmingham, Birmingham, UK. anthony.kong@kcl.ac.uk.
Purpose Of Review:
WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells although not exclusively. Here, we review the clinical development of WEE1 inhibitor in combination with chemotherapy or radiotherapy with concurrent chemotherapy as well as its combination with different novel agents.
Recent Findings:
Although several clinical trials have shown that WEE1 inhibitor can be safely combined with different chemotherapy agents as well as radiotherapy with concurrent chemotherapy, its clinical development has been hampered by the higher rate of grade 3 toxicities when added to standard treatments. A few clinical trials had also been conducted to test WEE1 inhibitor using TP53 mutation as a predictive biomarker. However, TP53 mutation has not been shown to be the most reliable predictive biomarker and the benefit of adding WEE1 inhibitor to chemotherapy has been modest, even in TP53 biomarker-driven studies. There are ongoing clinical trials testing WEE1 inhibitor with novel agents such as ATR and PAPR inhibitors as well as anti-PDL1 immunotherapy, which may better define the role of WEE1 inhibitor in the future if any of the novel treatment combination will show superior anti-tumor efficacy with a good safety profile compared to monotherapy and/or standard treatment.
Insights
WEE1 inhibitors show promise in enhancing cancer treatment sensitivity, but clinical trials reveal challenges with toxicity and modest benefits. Future research focuses on novel combinations to improve efficacy and safety.
Area of Science:
- Oncology
- Cancer Therapeutics
- Clinical Trials
Background:
- WEE1 inhibitor demonstrates potential in sensitizing cancer cells to chemotherapy and radiotherapy, particularly in p53-mutated or deficient cancers.
- Preclinical models suggest WEE1 inhibition can enhance treatment sensitivity.
Purpose of the Study:
- To review the clinical development of WEE1 inhibitors in combination therapies.
- To evaluate WEE1 inhibitor combinations with chemotherapy, radiotherapy, and novel agents.
Main Methods:
- Review of clinical trial data for WEE1 inhibitor combinations.
- Analysis of safety and efficacy of WEE1 inhibitor in various treatment settings.
Main Results:
- Clinical trials indicate WEE1 inhibitors can be safely combined with chemotherapy and radiotherapy.
- Higher rates of grade 3 toxicities observed when WEE1 inhibitors are added to standard treatments.
- TP53 mutation status has not proven to be a reliable predictive biomarker for WEE1 inhibitor efficacy.
- Modest clinical benefits observed even in TP53 biomarker-driven studies.
Conclusions:
- WEE1 inhibitor development faces challenges due to toxicity and modest efficacy in current combinations.
- Ongoing trials exploring WEE1 inhibitors with novel agents (ATR inhibitors, PARP inhibitors, anti-PDL1 immunotherapy) may redefine its future role.
- Future success depends on identifying combinations with superior anti-tumor efficacy and favorable safety profiles.
Related Concept Videos
01:28Preclinical Development: Overview
02:54Canonical Wnt Signaling Pathway